Conference: 2014 International PHA Conference and Scientific Sessions
Release Date: 03.27.2017
Roham Zamanian, M.D.
Stanford University Medical Center
To support the attainment of knowledge, competence, and performance, the learner should be able to achieve the following objectives:
Discuss the impact of methamphetamine dependence and abuse on PAH therapy selection
Review subtle presentations of inappropriate response to vasodilator therapies
Discuss the interpretation of inappropriate therapy response and medical management in such scenario
This educational activity is intended for;
Unapproved/Off-Label Use Disclosure
When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved)
Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for educational purposes and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Faculty, Planners, Staff Disclosure Information
All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity.
The faculty and planners of this educational activity disclose the following:
Roham Zamanian, M.D., indicates no significant relationships to disclose.
PHA and PESG Staff have no relevant financial relationships to disclose.